Manufacturer record
HML Pharmaceuticals LLP: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by HML Pharmaceuticals LLP (Chhattisgarh) was declared Not of Standard Quality in September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: T25044, Cefpodoxime Dispersible Tablets 200 mg (exp Jan 2027). SDTL, Uttarakhand (state lab) found it not of standard quality: IDENTIFICATION TEST: No peak observed in Chromatogram of Cefpodoxime I.P. (Does not comply with I.P.). 02. ASSAY OF CEFPODOXIME TRIHYDRATE. Listed in the September 2026 alert.
Records by type
1 record linked to HML Pharmaceuticals LLP in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefpodoxime Dispersible Tablets 200 mg | Batch T25044Mfg Feb 2025 · Exp Jan 2027 | IDENTIFICATION TEST: No peak observed in Chromatogram of Cefpodoxime I.P. (Does not comply with I.P.). 02. ASSAY OF CEFPODOXIME TRIHYDRATE I.P. ?NIL.Assay | SDTL, UttarakhandState lab | Sep 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.